AbbVie (NYSE:ABBV) Reaches New 52-Week High - Here's Why

Key Points

• AbbVie shares reached a new 52-week high of $281.30, supported by expectations for continued growth from Skyrizi and Rinvoq as Humira sales decline.
• Analyst sentiment remains favorable, with several firms raising price targets; AbbVie has a consensus rating of “Moderate Buy” and an average target of $277.18.
• AbbVie reported 10.2% year-over-year quarterly revenue growth and earnings above expectations, while maintaining a quarterly dividend of $1.73 per share, yielding approximately 2.5%.

AbbVie Inc. (NYSE:ABBV - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday. The stock traded as high as $281.30 and last traded at $280.8740, with a volume of 5,593,125 shares changing hands. The stock had previously closed at $276.47.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Skyrizi and Rinvoq remain the central growth drivers. Analysts expect the two medicines to deliver strong Q3 revenue growth and help counter Humira’s continuing sales erosion. However, increasing competition in immunology remains a consideration. Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?
• Positive Sentiment: Long-term clinical data for SKYRIZI and RINVOQ provided additional pipeline support. AbbVie highlighted findings at the ACG 2026 conference, helping support confidence in the therapies’ durability and commercial potential. AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings At ACG 2026
• Positive Sentiment: Analyst backing remains supportive. Guggenheim reaffirmed a Buy rating, while a separate report cited an analyst upgrade. These actions suggest that some analysts see further upside despite ABBV’s substantial recent gains. AbbVie Stock Rating Reaffirmed as Buy by Guggenheim
• Positive Sentiment: Investors continue to view AbbVie as a durable income and growth holding. Although the dividend yield has fallen because the share price has risen faster than the dividend, the company’s payout record and expanding product portfolio remain attractive to income investors. AbbVie's Dividend Yield Is at Its Lowest Level Since 2018
• Neutral Sentiment: Broader biotech sentiment is improving as pharmaceutical companies pursue acquisitions to replenish pipelines ahead of patent expirations. This could benefit AbbVie’s sector valuation, but it also underscores the industry’s broader patent-cliff pressures. Biotech's Rebound Reality
• Negative Sentiment: Humira’s decline and rising competition could limit near-term growth if Skyrizi and Rinvoq do not continue gaining market share. Valuation is also a risk, with Wall Street price targets showing a wide gap between bullish and bearish expectations. AbbVie's Next Billion-Dollar Opportunity Is Taking Shape

Analyst Ratings Changes

Several brokerages have issued reports on ABBV. JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $285.00 to $300.00 and gave the stock an "overweight" rating in a research note on Thursday, October 8th. HSBC boosted their target price on AbbVie from $300.00 to $315.00 and gave the company a "buy" rating in a research report on Thursday, September 10th. Morgan Stanley upped their target price on AbbVie from $296.00 to $310.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. Bank of America reiterated a "buy" rating on shares of AbbVie in a report on Tuesday, September 8th. Finally, Leerink Partners increased their price target on AbbVie from $245.00 to $279.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and a consensus price target of $277.18.

AbbVie Stock Performance

The business's fifty day moving average is $259.79 and its two-hundred day moving average is $237.39. The company has a market cap of $496.25 billion, a P/E ratio of 79.34, a price-to-earnings-growth ratio of 1.26 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same period in the previous year, the company earned $2.97 EPS. The firm's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts expect that AbbVie Inc. will post 13.94 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. AbbVie's payout ratio is 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.06% of the company's stock.

Institutional Trading of AbbVie

A number of hedge funds have recently added to or reduced their stakes in ABBV. State Street Corp increased its stake in shares of AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company's stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares in the last quarter. Corient Private Wealth LP purchased a new position in AbbVie in the 2nd quarter valued at about $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock worth $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Legal & General Group Plc acquired a new stake in AbbVie in the 2nd quarter worth about $2,905,952,000. Finally, Deutsche Bank AG boosted its holdings in AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock worth $2,710,905,000 after buying an additional 1,241,587 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.